Forma Life Sciences launches a U.S. CDMO focused on oral solid drug manufacturing. Discover what the move means for pharma supply chains and drug development.
AN2 Therapeutics plans a Phase 2 trial of epetraborole for polycythemia vera. Explore what this strategy could mean for future hematology treatments.
ARPA-H backs Seaport Therapeutics’ GlyphCele program targeting gut lymphatics in metabolic disease and pancreatic cancer. Read the analysis.
Affinia Therapeutics’ AFTX-201 wins FDA Fast Track for BAG3 cardiomyopathy. Explore what this means for cardiac gene therapy and future heart failure treatments.
Persevere Therapeutics launches misetionamide trial in platinum-resistant ovarian cancer. Discover what this dual-pathway strategy could mean for treatment.
Psyence Biomedical Ltd. advances natural psilocybin therapy in a Phase IIb cancer distress trial. Explore what this means for psychedelic medicine development.
Can Propanc Biopharma’s PRP therapy disrupt pancreatic cancer treatment? Explore the science, risks, and market implications of this emerging oncology approach.
Japan approves high-dose BESREMi regimen for polycythemia vera. Read the full analysis on safety, adoption, and what clinicians will watch next.
New HSS data challenge assumptions on aspirin, NSAIDs, and cefazolin in joint replacement. See what this means for bleeding, pain, and infection risk.
Acadia seeks EU re-examination after CHMP rejects trofinetide for Rett syndrome. Read the regulatory and clinical implications.